AR and posterior cortical atrophy: Since the development of PCa is inextricably linked to the androgen receptor (AR), ADT therapy is generally effective for treatment-naive tumors; this is also called the hormone-sensitive prostate cancer (HSPC) stage, for which AR signaling inhibitors (ARSIs) with AR antagonism (such as enzalutamide) or androgen synthesis inhibition (such as abiraterone acetate), as well as gonadotropin-releasing hormone (GnRH) agonists and antagonists (such as degarelix), are often chosen.